Actively Recruiting
Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks
Led by AbbVie · Updated on 2026-02-10
189
Participants Needed
3
Research Sites
56 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Migraine is a neurological disease characterized by moderate or severe headaches, associated with nausea, vomiting, and/or sensitivity to light and sound. This study will assess changes in migraine attack severity for adult participants treating with oral ubrogepant across migraine attacks. Ubrogepant is a drug that is approved for the acute treatment of migraine in adults. Approximately 189 participants will be enrolled in approximately 15 sites across the US. Participants will receive ubrogepant as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 13 weeks. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
CONDITIONS
Official Title
Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks
Who Can Participate
Eligibility Criteria
You may qualify if you...
- History of 4 to 10 migraine days per month with moderate to severe headache pain in each of the 3 months before Visit 1
- Participants with chronic migraine reporting 4 to 10 migraine days per month with moderate to severe headache pain in each of the 3 months before Visit 1 due to preventive treatment are allowed
- Currently prescribed ubrogepant and using it for at least 3 months for acute migraine treatment according to FDA-approved use
- Adult participants with a current clinical diagnosis of migraine or chronic migraine according to ICHD-3
You will not qualify if you...
- Currently participating in another clinical or non-interventional study
- Using a strong Cytochrome P450 3A4 (CYP3A4) inhibitor
- Current diagnosis of new persistent daily headache, trigeminal autonomic cephalgia, status migrainosus, or painful cranial neuropathy as defined by ICHD-3
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Neurology and Pain Specialty Center /ID# 278508
Aliso Viejo, California, United States, 92656
Actively Recruiting
2
Chicago Headache Center & Research Inst /ID# 272345
Naperville, Illinois, United States, 60563
Actively Recruiting
3
Tri City Research Center, LLC /ID# 278800
Grand Island, Nebraska, United States, 68803
Actively Recruiting
Research Team
K
Krystal Spenta
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here